Phaseline

Companies › Phanes Therapeutics

Phanes Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Mavrostobart (PT199)
anti-CD73 monoclonal antibody
NT5EPhase 1Non Small Cell Lung CancerDec 2027
Peluntamig (PT217)
Bispecific antibody against DLL3 and CD47
DLL3, CD47Phase 1Small Cell Lung Cancer (SCLC)Dec 2027
Spevatamig (PT886)
Bispecific antibody targeting Claudin 18.2 and CD47
CLDN18, CD47Phase 1Gastric or Gastroesophageal Junction AdenocarcinomaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05431270Mavrostobart (PT199)Phase 1Non Small Cell Lung CancerOncologyDec 2027
NCT05652686Peluntamig (PT217)Phase 1Small Cell Lung Cancer (SCLC)OncologyDec 2027
NCT05482893Spevatamig (PT886)Phase 1Gastric or Gastroesophageal Junction AdenocarcinomaOncologyDec 2027

Targets

CD47 (2) NT5E (1) DLL3 (1) CLDN18 (1)

Companies with the same targets

AstraZeneca Akeso Novartis Astellas Boehringer Ingelheim Beijing Biotech ALX Oncology Pfizer Suzhou Suncadia Biopharmaceuticals Ono Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.